Enshuxing (enlonstobart) / CSPC Pharma, Sumgen Biotech - LARVOL DELTA

Preliminary results of enlonstobart combined with weekly chemotherapy (induction phase) followed by concurrent immunochemoradiotherapy in locally advanced cervical cancer: a multicenter, single-arm study (SGO 2026) - No abstract available

Clinical • Metastases • Cervical Cancer • Oncology • Solid Tumor

A single-arm exploratory clinical study on the sequential concurrent chemoradiotherapy with Enlonstobart in the treatment of locally advanced cervical cancer (SGO 2026) - No abstract available

Clinical • Metastases • Cervical Cancer • Oncology • Solid Tumor

Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC (clinicaltrials.gov) - P2 | N=128 | Not yet recruiting | Sponsor: Hebei Medical University Fourth Hospital

New P2 trial • pMMR • Colon Adenocarcinoma • Colon Cancer • Colorectal Cancer • Oncology • Rectal Cancer • Solid Tumor

The Comparative Effectiveness of Enlonstobart and Camrelizumab as Second-Line Recurrent or Metastatic Cervical Cancer Therapies: Matching-Adjusted and Simulated Treatment Comparisons. (PubMed, Immunotargets Ther) - "This indirect comparison demonstrated that enlonstobart provided a significant OS advantage compared to camrelizumab in patients with second-line R/M CC. These findings suggest enlonstobart may represent a promising therapeutic option for PD-(L)1 positive R/M CC patients."

HEOR • Journal • Cervical Cancer • Oncology • Solid Tumor

Phase II/III Trial of SYS6010 plus Enlonstobart Injection ± Chemotherapy in Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ChiCTR) - P2/3 | N=737 | Not yet recruiting | Sponsor: Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center

New P2/3 trial • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma • PD-L1

Phase I/II clinical study of SYS6043 combined with PD-1/PD-L1 inhibitor ± chemotherapy in the treatment of advanced solid tumor participants (ChiCTR) - P1/2 | N=622 | Not yet recruiting | Sponsor: Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center

New P1/2 trial • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer (clinicaltrials.gov) - P2/3 | N=490 | Not yet recruiting | Sponsor: Shanghai JMT-Bio Inc.

New P2/3 trial • Gastric Cancer • Oncology • Solid Tumor • HER-2 • PD-L1

JMT101 in combination with irinotecan and SG001 versus regorafenib in patients with metastatic colorectal adenocarcinoma (mCRC): Results of a randomized, controlled, open-label, phase II study. (ASCO 2025) - P2 | "Our results demonstrated a promising response rate and a tolerable safety profile of JMT101 + irinotecan +/- SG001 in pts with mCRC. Preliminary data support continued investigation, with updated results to follow. Clinical trial information: NCT06089330."

Clinical • Combination therapy • IO biomarker • Late-breaking abstract • Metastases • P2 data • Colorectal Adenocarcinoma • Colorectal Cancer • Microsatellite Instability • Oncology • Solid Tumor • BRAF • MSI • PD-L1

A single-Arm, Open-Label Ib/II Study of Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma(PTCL) (ChiCTR) - P1/2 | N=43 | Not yet recruiting | Sponsor: Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center

New P1/2 trial • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

An open-label, multicenter, phase II study to evaluate the efficacy and safety of SYS6010 combined with enlonstobart in the recurrent or metastatic head and neck squamous cell carcinoma (ChiCTR) - P2 | N=70 | Not yet recruiting | Sponsor: Shanghai East Hospital, Tongji University(Shanghai East Hospital); Shanghai East Hospital, Tongji University(Shanghai East Hospital)

New P2 trial • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • PD-L1

SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma (clinicaltrials.gov) - P2 | N=70 | Recruiting | Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • PD-L1

Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) (clinicaltrials.gov) - P1/2 | N=43 | Not yet recruiting | Sponsor: Sun Yet-Sen University Cancer Center

New P1/2 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer (clinicaltrials.gov) - P1/2 | N=116 | Not yet recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

New P1/2 trial • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Phase 1b Multicenter Study of SG001, a Humanized Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors. (PubMed, Drug Des Devel Ther) - P1 | "The safety profile was well tolerated. ClinicalTrials.gov identifier: NCT03852823."

Clinical • Journal • P1 data • Epstein-Barr Virus Infections • Lung Cancer • Mesothelioma • Microsatellite Instability • Non Small Cell Lung Cancer • Oncology • Renal Disease • Solid Tumor • MSI • PD-L1

SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma (clinicaltrials.gov) - P2 | N=70 | Not yet recruiting | Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.

New P2 trial • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma. (clinicaltrials.gov) - P2/3 | N=737 | Not yet recruiting | Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.

IO biomarker • New P2/3 trial • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma • PD-L1

A Phase II Clinical Study of SYS6002 in combination with SG001 in patients with advanced urothelial cancer and other advanced solid tumor (ChiCTR) - P2 | N=148 | Recruiting | Sponsor: Fudan University Shanghai Cancer Center; CSPC Megalith Biopharmaceutical Co., Ltd..

New P2 trial • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC (clinicaltrials.gov) - P2 | N=430 | Not yet recruiting | Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. | N=250 ➔ 430 | Initiation date: May 2025 ➔ Aug 2025 | Trial primary completion date: Sep 2027 ➔ Dec 2027

Enrollment change • Trial initiation date • Trial primary completion date • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

A single-arm, single-center, exploratory, phase II clinical study of spatially fractionated radiotherapy (lattice SFRT) combined with enlonstobart in the treatment of recurrent/metastatic bulky gynecological malignancies (ChiCTR) - P2 | N=20 | Not yet recruiting | Sponsor: Sichuan Cancer Hospital; Sichuan Cancer Hospital

New P2 trial • Gynecologic Cancers • Oncology

The efficacy and safety of combined chemotherapy and immunotherapy as neoadjuvant therapy for advanced cervical cancer (ChiCTR) - P=N/A | N=20 | Recruiting | Sponsor: Jilin Cancer Hospital; Jilin Cancer Hospital

New trial • Cervical Cancer • Oncology • Solid Tumor

Enlonstobart in patients with PD-L1 positive recurrent/metastatic cervical cancer: Updated survival results of the phase II study. (ASCO 2025) - P2 | "Enlonstobart monotherapy showed a promising survival in patients with PD-L1 positive recurrent/metastatic cervical cancer, whose disease experienced progression after first-line platinum-based therapy."

Clinical • Metastases • P2 data • Cervical Cancer • Oncology • Solid Tumor • PD-L1

JSKN003 Combined Treatment of HER2-positive Gastric Cancer (clinicaltrials.gov) - P2 | N=153 | Not yet recruiting | Sponsor: Shanghai JMT-Bio Inc.

New P2 trial • Gastric Cancer • Oncology • Solid Tumor

SYS6002 Plus JMT101 and Enlonstobart Injection as First-Line Treatment for HNSCC (clinicaltrials.gov) - P2 | N=250 | Not yet recruiting | Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.

New P2 trial • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

A Single-Arm Exploratory Study of Enlansibumab Sequentially Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer (clinicaltrials.gov) - P2 | N=34 | Not yet recruiting | Sponsor: Chongqing University Cancer Hospital

New P2 trial • Cervical Cancer • Oncology • Solid Tumor

Enlonstobart (SG001) plus platinum-based chemotherapy ± bevacizumab for first-line treatment of PD-L1 positive recurrent/metastatic cervical cancer: safety run-in results of the phase III randomized, double-blind, placebo-controlled study (SGO 2025) - No abstract available

Clinical • Metastases • P3 data • Cervical Cancer • Oncology • Solid Tumor • PD-L1